As of 12:30 PM on the 18th, Chong Kun Dang is trading at 205,000 KRW, down 2.61% from the previous day. The trading volume is 131,045 shares, which is about 22.22% of the previous day's volume. Chong Kun Dang is known as a leading pharmaceutical company in the industry, focusing on therapeutics.
On January 13, Minjeong Seon, a researcher at Hana Financial Investment, estimated that "Operating profit for 2021 is expected to slightly decrease compared to the previous year, reaching approximately 130 billion KRW due to a high base last year and increased marketing expenses returning to normal levels. This year's top-line growth is also expected to be in the high single digits as the growth of major products slows somewhat. However, attention should be paid to the growth of new products like Qsymia, which has rapidly grown to achieve quarterly sales exceeding 5 billion KRW within one year of launch. There is excessive optimism regarding COVID-19 therapeutics." She set the target price for Chong Kun Dang at 250,000 KRW.
Over the past five days, individual investors have net purchased 159,523 shares of Chong Kun Dang, while foreign investors and institutions have net sold 26,984 shares and 130,612 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
